Boothbay Fund Management’s SpringWorks Therapeutics SWTX Stock Holding History

Boothbay Fund Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,750	Closed	-$881K	–	2154
2025 Q2	$881K	Sell	18,750 -17,460	-48%	-$777K	0.02%	724
2025 Q1	$1.6M	Buy	36,210 +25,232	+230%	+$1.16M	0.04%	486
2024 Q4	$397K	Buy	+10,978	New	+$384K	0.01%	969
2023 Q4	–	Sell	-38,447	Closed	-$889K	–	1973
2023 Q3	$889K	Buy	+38,447	New	+$1.05M	0.02%	821
2021 Q3	–	Sell	-2,799	Closed	-$231K	–	2171
2021 Q2	$231K	Buy	+2,799	New	+$213K	0.01%	1437

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Boothbay Fund Management's SWTX Position: Q3 2025 in Review

Boothbay Fund Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 18,750 shares — an estimated $881K sold.

Boothbay Fund Management first reported a position in SWTX in Q2 2021 and held it in 5 quarters. The position peaked at $1.6M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Boothbay Fund Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Boothbay Fund Management sold 18,750 SpringWorks Therapeutics shares in Q3 2025, an estimated $881K.
Boothbay Fund Management first reported a position in SpringWorks Therapeutics in Q2 2021 and held it in 5 quarters.
Boothbay Fund Management's SpringWorks Therapeutics position peaked at $1.6M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.